Exciting Emerging Data in Prostate Cancer

Stephen J. Freedland, MD, highlights emerging data to look out for that might address unmet needs in prostate cancer testing and treatment.

EP: 1.Staging, Grading, and Risk Stratification of Prostate Cancer

EP: 2.Treatment Options for High-Risk, Clinically Localized Prostate Cancer

EP: 3.Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer

EP: 4.The Potential for Overtreatment or Undertreatment of Prostate Cancer

EP: 5.Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing

EP: 6.Available Genomic Tests for Clinically Localized Prostate Cancer

EP: 7.Clinical Study Data in Prostate Cancer Genomic Testing

EP: 8.Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

Now Viewing

EP: 9.Exciting Emerging Data in Prostate Cancer

Related Videos

Related Content

Advertisement

July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 3rd 2025

FDA news recap in urology for Q2 2025

Hannah Clarke Benjamin P. Saylor Jason M. Broderick

Here’s a look back at notable news between April and June 2025.

July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke

The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.

Related Content

Advertisement

July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke

Take a look through all the regulatory milestones in urology from the first half of the 2025.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

July 3rd 2025

FDA news recap in urology for Q2 2025

Hannah Clarke Benjamin P. Saylor Jason M. Broderick

Here’s a look back at notable news between April and June 2025.

July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke

The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.